Skip to content
[P]pubcas
Independent chemical reference Compare
Chemical substance record

Gemcitabine

95058-81-4C9H11F2N3O4263.2 g/mol

A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer. — ChEBI

Safety references

Safety documents & references

Supplier matching matters

Find the safety document for your specific supplier, product number and grade.

Find a product-specific SDS

Safety guides and government classification records are not a manufacturer’s SDS. Match supplier, product number, concentration, physical form, region and revision before using a document.

Identity & molecular properties

Source-linked values
CAS number95058-81-4ChEBI ↗
Molecular formulaC9H11F2N3O4ChEBI ↗
Molar mass263.2 g/molChEBI ↗
Monoisotopic mass263.07176 DaChEBI ↗
Formal charge0ChEBI ↗
ChEBI identifierCHEBI:175901ChEBI ↗

Cross-source molecular data

PubChem
Molar mass263.20 g/molPubChem ↗
Exact mass263.07176216 DaPubChem ↗
Computed XLogP-1.5PubChem ↗
Topological polar surface area (Ų)108PubChem ↗
H-bond donors3PubChem ↗
H-bond acceptors6PubChem ↗
Rotatable bonds2PubChem ↗

PubChem computed values are shown separately from the ChEBI record. An exact InChIKey match was used to connect the records. Molecular descriptors do not describe a supplied product’s purity, particle size or performance.

Names & structural identifiers

Copy any identifier
gemcitabine
2'-deoxy-2',2'-difluorocytidine
SDUQYLNIPVEERB-QPPQHZFASA-N
Nc1ccn([C@@H]2O[C@H](CO)[C@@H](O)C2(F)F)c(=O)n1
InChI=1S/C9H11F2N3O4/c10-9(11)6(16)4(3-15)18-7(9)14-2-1-5(12)13-8(14)17/h1-2,4,6-7,15-16H,3H2,(H2,12,13,17)/t4-,6-,7-/m1/s1

Names & synonyms

2'-deoxy-2',2'-difluorocytidinegemcitabinagemcitabinum

Names are supplied by ChEBI. Trade names and related synonyms may describe a broader product context.

Classification & relationships

ChEBI ontology

Roles recorded in ChEBI

radiosensitizing agentantimetaboliteanxiolytic drugantineoplastic agentxenobioticimmunosuppressive agentantiviral drugphotosensitizing agentprodrugDNA synthesis inhibitor

Database role annotations describe reported biological or chemical roles; they are not product approvals or recommendations for use.

Mass ↔ amount of substance

Calculated from sourced mass
Equivalent amount
0.00379939 mol

Uses 263.2 g/mol from ChEBI. Assumes the substance described by this record; no purity or concentration correction is applied.

Elemental composition

Theoretical mass fractions
C
Carbon · 9 atoms
41.07%
O
Oxygen · 4 atoms
24.31%
N
Nitrogen · 3 atoms
15.97%
F
Fluorine · 2 atoms
14.44%
H
Hydrogen · 11 atoms
4.21%

Calculated theoretical mass fractions from the reported formula and PubChem periodic-table atomic masses. These are not assay or purity results.

Research & patent references

Selected source associations
Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction. ↗Annals of oncology : official journal of the European Society for Medical Oncology · 2000 Sep · PMID 11061612
EP1939198 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
EP2108368 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.
EP2275135 · Patent reference ↗Patent cross-reference supplied by ChEBI. Association alone does not establish claim scope.

Sources & record history

Checked 27 Sep 2026
EMBL-EBI ChEBI · CHEBI:175901

Release 255, 9 September 2026. ChEBI three-star (manually annotated) source entry. View original record ↗ · CC BY 4.0

NCBI PubChem · CID 60750 · retrieved 2026-09-27

PubCAS formats source data, connects references and computes explicitly labelled conversions. CAS cross-references are supplied by ChEBI; they do not constitute CAS verification or endorsement.